Summary At the European Society for Medical Oncology (ESMO) 2022 annual meeting, several pertinent studies in field of upper gastrointestinal cancer were presented. The most practice-changing study appeared to be Destiny-Gastric02 evaluating trastuzumab–deruxtecan as a second-line treatment option patients with Her2-positive gastric and gastroesophageal junction cancer. median overall survival ...

Upper gastrointestinal bleeding is one of the commonest emergencies encountered by general physicians. Once haemodynamic stability has been achieved, therapeutic endoscopy is vital in control and arrest of bleeding. Various methods are available and the evidence is reviewed as to the most optimal approach. Clinical parameters including timing of endoscopy, risk stratification, and predictors of...

Endoscopy was performed in 194 patients who presented with upper gastrointestinal haemorrhage from January 1986 through June 1987. A cause of bleeding was identified in 187 cases (96.4%). The most common cause was duodenal ulcer which was evident in 84 cases (43.3%). Endoscopic proof of bleeding was seen in 122 patients (65.2%) while an assumed cause was designated in 65 cases (34.8%). Endoscop...